Anti -Complement C3, Activated

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 9; NC_000009.11 (123714613..123812554, complement). Location: 9q33-q34

Monoclonal

IgG2a

bH6

Mouse

Recognizes a neo-epitope expressed on the cleavage fragments of C3b, iC3b and C3c, but not C3dg and C3f.

Affinity Purified
Purified by Protein G affinity chromatography.

Supplied as as liquid in PBS, 0.1% BSA, 0.02% sodium azide.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-C5 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3mg/ml. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported.

Antibodies; Abs to Complement

ELISA (EL/EIA), Immunohistochemistry (IHC)

Suitable for use in ELISA and Immunohistochemistry.
Dilution: ELISA: Detects and/or quantifies C3 activation products in human plasma, synovial fluid and cerebrospinal fluid
Immunohistochemistry (Paraffin, frozen): 1:50

188,305 Da[Similar Products]

complement component 5

complement C5; prepro-C5; C5a anaphylatoxin; anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4

Complement C5

CPAMD4??[Similar Products]

CO5_HUMAN

The protein encoded by this gene is the fifth component of complement, which plays an important role in inflammatory and cell killing processes. This protein is comprised of alpha and beta polypeptide chains that are linked by a disulfide bridge. An activation peptide, C5a, which is an anaphylatoxin that possesses potent spasmogenic and chemotactic activity, is derived from the alpha polypeptide via cleavage with a convertase. The C5b macromolecular cleavage product can form a complex with the C6 complement component, and this complex is the basis for formation of the membrane attack complex, which includes additional complement components. Mutations in this gene cause complement component 5 deficiency, a disease where patients show a propensity for severe recurrent infections. Defects in this gene have also been linked to a susceptibility to liver fibrosis and to rheumatoid arthritis. [provided by RefSeq, Jul 2008]

C5: Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Defects in C5 are the cause of complement component 5 deficiency (C5D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 9q33-q34

Cellular Component: membrane attack complex; extracellular space; extracellular region

Molecular Function: protein binding; chemokine activity; endopeptidase inhibitor activity; receptor binding; C5a anaphylatoxin chemotactic receptor binding

Biological Process: in utero embryonic development; positive regulation of chemotaxis; activation of MAPK activity; cytolysis; complement activation, alternative pathway; glucose homeostasis; chemotaxis; leukocyte migration during inflammatory response; complement activation; cellular calcium ion homeostasis; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; cell surface receptor linked signal transduction; regulation of complement activation; innate immune response; response to stress; inflammatory response; negative regulation of dopamine secretion; complement activation, classical pathway

Disease: Complement Component 5 Deficiency; Eculizumab, Poor Response To

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.